
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA added another approval for ropeginterferon alfa-2b-njft (Besremi) based on the phase 3 SURPASS-ET trial (NCT04285086). In which myeloproliferative neoplasm is the agent now approved?






